Aeterna Zentaris Announces Proposed Public Offering of Common Shares and Warrants
December 08 2015 - 4:15PM
Business Wire
Aeterna Zentaris Inc. (NASDAQ: AEZS; TSX: AEZ)
(the “Company”) today announced that it has commenced an
underwritten public offering (the “Offering”) of common shares and
warrants to purchase common shares. Investors whose purchase of
common shares in the Offering would result in them beneficially
owning more than the initial beneficial ownership limitation to be
included in the warrants following the consummation of the Offering
will have the opportunity to acquire pre-funded warrants
substituted for any common shares they would have otherwise
acquired over the initial beneficial ownership limitation, paying
the same price per share. The pricing and number of shares and
warrants as well as the exercise price and duration of the warrants
will be determined in the course of marketing.
Maxim Group LLC is acting as sole book-running manager for the
proposed Offering. The proposed Offering is subject to customary
conditions, including the approval of The NASDAQ Stock Market
(“NASDAQ”) and the Toronto Stock Exchange (“TSX”), and there can be
no assurance as to whether or when the proposed Offering may be
completed, or as to the actual size or terms of the Offering. The
Company has no intention of listing the warrants on the NASDAQ or
TSX.
The Offering is being conducted pursuant to the Company’s
effective shelf registration statement on Form F-10 filed with the
U.S. Securities and Exchange Commission (the “SEC”), its
corresponding Canadian base shelf prospectus and an exemption from
the Autorité des marches financiers permitting the Company to offer
common shares, warrants and such other securities specified therein
in the United States. The proposed Offering will be made only by
means of a preliminary prospectus supplement, a final prospectus
supplement and the accompanying short form base shelf prospectus.
When available, copies of the preliminary prospectus supplement,
the final prospectus supplement and the accompanying short form
base shelf prospectus may be obtained upon request by contacting
Maxim Group LLC, 405 Lexington Avenue, 2nd Floor, New York, NY
10174, (212) 895-3745. Electronic copies of the preliminary
prospectus supplement, the final prospectus supplement and the
accompanying short form base shelf prospectus will also be
available free of charge at www.sedar.com and www.sec.gov,
respectively.
This press release does not and shall not constitute an offer
to sell or the solicitation of an offer to buy any of the Company’s
securities, nor shall there be any sale of the Company’s securities
in any state or jurisdiction in which such offer, solicitation or
sale would be unlawful prior to registration or qualification under
the securities laws of any such state or jurisdiction.
About Aeterna Zentaris Inc.
Aeterna Zentaris is a specialty biopharmaceutical company
engaged in developing and commercializing novel treatments in
oncology, endocrinology and women’s health. We are engaged in drug
development activities and in the promotion of products for others.
The focus of our business development efforts is the acquisition of
licenses to products that are relevant to our therapeutic areas of
focus. We also intend to license out certain commercial rights of
internally developed products to licensees in territories where
such out-licensing would enable us to ensure development,
registration and launch of our product candidates. Our goal is to
become a growth-oriented specialty biopharmaceutical company by
pursuing successful development and commercialization of our
product portfolio, achieving successful commercial presence and
growth, while consistently delivering value to our shareholders,
employees and the medical providers and patients who will benefit
from our products. For more information, visit www.aezsinc.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20151208006638/en/
Aeterna Zentaris Inc.Philip TheodoreSenior Vice
President843-900-3223ptheodore@aezsinc.com
Aeterna Zentaris (NASDAQ:AEZS)
Historical Stock Chart
From Jul 2024 to Aug 2024
Aeterna Zentaris (NASDAQ:AEZS)
Historical Stock Chart
From Aug 2023 to Aug 2024